142 related articles for article (PubMed ID: 2514364)
21. [Comparison of the affinities of amoxapine and loxapine for various receptors in rat brain and the receptor down-regulation after chronic administration].
Wei HB; Niu XY
Yao Xue Xue Bao; 1990; 25(12):881-5. PubMed ID: 1966571
[TBL] [Abstract][Full Text] [Related]
22. Pharmacological profile of binedaline, a new antidepressant drug.
Morin D; Zini R; Urien S; Tillement JP
J Pharmacol Exp Ther; 1989 Apr; 249(1):288-96. PubMed ID: 2540319
[TBL] [Abstract][Full Text] [Related]
23. Synthesis and serotonin receptor affinities of a series of trans-2-(indol-3-yl)cyclopropylamine derivatives.
Vangveravong S; Kanthasamy A; Lucaites VL; Nelson DL; Nichols DE
J Med Chem; 1998 Dec; 41(25):4995-5001. PubMed ID: 9836617
[TBL] [Abstract][Full Text] [Related]
24. Phenyliminoimidazolidines. Characterization of a class of potent agonists of octopamine-sensitive adenylate cyclase and their use in understanding the pharmacology of octopamine receptors.
Nathanson JA
Mol Pharmacol; 1985 Sep; 28(3):254-68. PubMed ID: 2993848
[TBL] [Abstract][Full Text] [Related]
25. Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors. Significance for the modulation of frontocortical monoaminergic transmission and depressive states.
Millan MJ; Newman-Tancredi A; Audinot V; Cussac D; Lejeune F; Nicolas JP; Cogé F; Galizzi JP; Boutin JA; Rivet JM; Dekeyne A; Gobert A
Synapse; 2000 Feb; 35(2):79-95. PubMed ID: 10611634
[TBL] [Abstract][Full Text] [Related]
26. Receptor alterations associated with serotonergic agents: an autoradiographic analysis.
Wamsley JK; Byerley WF; McCabe RT; McConnell EJ; Dawson TM; Grosser BI
J Clin Psychiatry; 1987 Mar; 48 Suppl():19-25. PubMed ID: 3029045
[TBL] [Abstract][Full Text] [Related]
27. Preclinical pharmacology of a new serotonergic receptor antagonist, LY281067.
Cohen ML; Fuller RW; Kurz KD; Parli CJ; Mason NR; Meyers DB; Smallwood JK; Toomey RE
J Pharmacol Exp Ther; 1988 Jan; 244(1):106-12. PubMed ID: 3335993
[TBL] [Abstract][Full Text] [Related]
28. Identification of serotonin 5-HT3 recognition sites in membranes of N1E-115 neuroblastoma cells by radioligand binding.
Hoyer D; Neijt HC
Mol Pharmacol; 1988 Mar; 33(3):303-9. PubMed ID: 3352595
[TBL] [Abstract][Full Text] [Related]
29. Selective 5-hydroxytryptamine2 antagonists have antidepressant-like effects on differential-reinforcement-of-low-rate 72-second schedule.
Marek GJ; Li AA; Seiden LS
J Pharmacol Exp Ther; 1989 Jul; 250(1):52-9. PubMed ID: 2746510
[TBL] [Abstract][Full Text] [Related]
30. Hallucinogenic drug interactions at human brain 5-HT2 receptors: implications for treating LSD-induced hallucinogenesis.
Sadzot B; Baraban JM; Glennon RA; Lyon RA; Leonhardt S; Jan CR; Titeler M
Psychopharmacology (Berl); 1989; 98(4):495-9. PubMed ID: 2505289
[TBL] [Abstract][Full Text] [Related]
31. 5-HT1 and 5-HT2 binding properties of derivatives of the hallucinogen 1-(2,5-dimethoxyphenyl)-2-aminopropane (2,5-DMA).
Shannon M; Battaglia G; Glennon RA; Titeler M
Eur J Pharmacol; 1984 Jun; 102(1):23-9. PubMed ID: 6479216
[TBL] [Abstract][Full Text] [Related]
32. Pharmacologic profile of MDMA (3,4-methylenedioxymethamphetamine) at various brain recognition sites.
Battaglia G; Brooks BP; Kulsakdinun C; De Souza EB
Eur J Pharmacol; 1988 Apr; 149(1-2):159-63. PubMed ID: 2899513
[TBL] [Abstract][Full Text] [Related]
33. Monoamine transporter and receptor interaction profiles of novel psychoactive substances: para-halogenated amphetamines and pyrovalerone cathinones.
Rickli A; Hoener MC; Liechti ME
Eur Neuropsychopharmacol; 2015 Mar; 25(3):365-76. PubMed ID: 25624004
[TBL] [Abstract][Full Text] [Related]
34. Hallucinogens and serotonergic mechanisms.
Glennon RA; Teitler M; Sanders-Bush E
NIDA Res Monogr; 1992; 119():131-5. PubMed ID: 1435968
[TBL] [Abstract][Full Text] [Related]
35. [Adrenergic and serotonergic receptors during depression and its therapy].
Krulík R; Fisar Z
Cesk Psychiatr; 1992 Sep; 88(5):229-36. PubMed ID: 1451201
[TBL] [Abstract][Full Text] [Related]
36. Effects of certain hallucinogenic amphetamine analogues on the release of [3H]serotonin from rat brain synaptosomes.
Nichols DE; Lloyd DH; Hoffman AJ; Nichols MB; Yim GK
J Med Chem; 1982 May; 25(5):530-5. PubMed ID: 7086839
[TBL] [Abstract][Full Text] [Related]
37. Behavioral and serotonin receptor properties of 4-substituted derivatives of the hallucinogen 1-(2,5-dimethoxyphenyl)-2-aminopropane.
Glennon RA; Young R; Benington F; Morin RD
J Med Chem; 1982 Oct; 25(10):1163-8. PubMed ID: 7143352
[TBL] [Abstract][Full Text] [Related]
38. Serotonergic functions in arousal and motor activity.
Geyer MA
Behav Brain Res; 1996; 73(1-2):31-5. PubMed ID: 8788473
[TBL] [Abstract][Full Text] [Related]
39. Selectivity of some ergot derivatives for 5-HT1 and 5-HT2 receptors of rat cerebral cortex.
Beart PM; McDonald D; Cincotta M; de Vries DJ; Gundlach AL
Gen Pharmacol; 1986; 17(1):57-62. PubMed ID: 3949149
[TBL] [Abstract][Full Text] [Related]
40. Chronic treatment with (+/-)DOI, a psychotomimetic 5-HT2 agonist, downregulates 5-HT2 receptors in rat brain.
McKenna DJ; Nazarali AJ; Himeno A; Saavedra JM
Neuropsychopharmacology; 1989 Mar; 2(1):81-7. PubMed ID: 2803482
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
